Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530344 · ClinicalTrials.gov registry record · Phase 3
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 458
- Enrollment target
NCT04530344 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 458 participants.
The verdict
NCT04530344, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 458 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.
Interventions
- DRUG Vehicle
- DRUG ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2022-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04530344
The ClinicalTrials.gov registry entry for NCT04530344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04530344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04530344 about?
NCT04530344 is a clinical study titled "Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo". The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies)...
What is the current status of trial NCT04530344?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 458 participants. The study started on 2020-09-24. Estimated completion is 2022-11-14.
What interventions are being tested in trial NCT04530344?
The interventions under investigation include: Vehicle (DRUG), ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04530344?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.